Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

3471 results about "Adipic acid" patented technology

Adipic acid or hexanedioic acid is the organic compound with the formula (CH₂)₄(COOH)₂. From an industrial perspective, it is the most important dicarboxylic acid: about 2.5 billion kilograms of this white crystalline powder are produced annually, mainly as a precursor for the production of nylon. Adipic acid otherwise rarely occurs in nature, but it is known as manufactured E number food additive E355.

Rapid acting and long acting insulin combination formulations

A combined rapid acting-long acting insulin formulation has been developed wherein the pH of the rapid acting insulin is adjusted so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day. Experiments have been performed to demonstrate, the importance of the addition of specific acids to hexameric insulin to enhance speed and amount of absorption and preserve bioactivity following dissociation into the monomeric form by addition of a chelator such as EDTA. As shown by the examples, the preferred acids are aspartic, maleic, succinic, glutamic and citric acid. These are added in addition to a chelator, preferably ethylenediaminetetraacetic acid (EDTA). The results show that the citric acid formulation was more effective at dropping the blood glucose rapidly than the identical rapid acting formulation prepared with HCl in swine. Charge masking by the polyacid appears to be responsible for rapid insulin absorption. EDTA was not effective when used with adipic acid, oxalic acid or HCl at hastening the absorption of insulin. These results confirm the results seen in clinical subjects and patients with diabetes treated with the rapid acting insulin in combination with citric acid and EDTA.
Owner:ELI LILLY & CO

Process and equipment for preparing adipic acid by catalyzing air and oxidizing cyclohexane

The invention discloses a process and a plant for preparing adipic acid by catalytically aerobically oxidizing cyclohexane. The process comprises the following steps: dissolving 1 to 50 PPM of a catalyst including single metalloporphyrin or mu-oxo bimetallic porphyrin or a mixture of single metalloporphyrin, mu-oxo bimetallic porphyrin and transition metal salt or oxide in cyclohexane; introducing 5 to 12 atm of air or oxygen-rich or oxygen-poor air into a multi-stage oxidation reactor with a gas distributor; controlling the reaction temperature at 140 to 160 DEG C; oxidizing cyclohexane for 45 to 120 min; feeding the mixture of the oxidation reaction into a flash separator to carry out flash evaporation at the temperature of 78 to 155 DEG C and under the pressure of 0.1 to 1.0 atm, so that the low-boiling-point products such as cyclohexane, cyclohexanol and cyclohexanone change to gas and are separated from adipic acid with the content above 80%; continuously circularly oxidizing the low-boiling-point products to separate and purify the high-boiling-point oxidation product; and purifying and separating by the existing technique to obtain fine adipic acid product. The process can directly prepare adipic acid by aerobically oxidizing cyclohexane, wherein the conversion rate of cyclohexane is up to 95%, and the yield of adipic acid is up to 70%.
Owner:HUNAN UNIV

Rapid Acting and Long Acting Insulin Combination Formulations

A combined rapid acting-long acting insulin formulation has been developed wherein the pH of the rapid acting insulin is decreased so that the long acting glargine remains soluble when they are mixed together. In the preferred embodiment, this injectable basal bolus insulin is administered before breakfast, provides adequate bolus insulin levels to cover the meal, does not produce hypoglycemia after the meal and provides adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of a fast acting, or a rapid acting or a very rapid acting insulin. As a result, a patient using intensive insulin therapy should only inject three, rather than four, times a day. Experiments have been performed to demonstrate the importance of the addition of specific acids to hexameric insulin to enhance speed and amount of absorption and preserve bioactivity following dissociation into the monomeric form by addition of a chelator such as EDTA. As shown by the examples, the preferred acids are aspartic, glutamic and citric acid. These are added in addition to a chelator, preferably ethylenediaminetetraacetic acid (EDTA). The results show that the citric acid formulation was more effective at dropping the blood glucose rapidly than the identical rapid acting formulation prepared with HCl in swine. Charge masking by the polyacid appears to be responsible for rapid insulin absorption. EDTA was not effective when used with adipic acid, oxalic acid or HCl at hastening the absorption of insulin. These results confirm the results seen in clinical subjects and patients with diabetes treated with the rapid acting insulin in combination with citric acid and EDTA.
Owner:ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products